Lung cancer is the leading cause of cancer death in the United States and worldwide. Majority of lung cancer patients require radiation as part of their treatment. Despite advances in radiation technology, treatment outcomes remain poor, with an overall cure rate of less than 10-15% and moderate toxicity in 10-30% of treated patients. Despite individual difference in their treatment outcome, the treatment is lack of individualization as there is no reliable way to predict which patient will have the cancer controlled and which patient will develop toxicity as a result of receiving a particular dose of radiation therapy to treat their lung cancer. Our preliminary results demonstrated that the during treatment PET scan was correlated with post-treatment response and long-term survival, and V/Q SPECT changed significantly during treatment, and the changes of SPECT and blood markers were predictive of late response. In the proposed clinical trial, we will validate above findings and use them during PET to guide individualized adaptive radiation dose escalation. We will enroll patients who have been diagnosed with non-small-cell lung cancers and are planning to receive radiation therapy as a part of their treatment. At midway during their course of radiation treatments, each patient will undergo PET/CT scan for measuring tumor activity/size and V/Q SPECT scan for mapping lung function. At three points during their course of radiation treatments, each patient will have blood drawn for markers. The results of these tests will be analyzed to determine their ability to accurately predict both the chance of long-term tumor control and the risk for developing lung toxicity. In the late phase of the grant period, we will further adapt the radiation treatment by the use of V/Q SPECT and blood marker during treatment so that the treatment gain could be maximized in each patient.

Public Health Relevance

This study will identify markers to predict treatment outcome for patients with lung cancer. This project will also study the potential for personalized care to improve treatment outcome.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA142840-06
Application #
8701876
Study Section
Radiation Therapeutics and Biology Study Section (RTB)
Program Officer
Deye, James
Project Start
2010-07-01
Project End
2016-04-30
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
6
Fiscal Year
2014
Total Cost
$70,396
Indirect Cost
$102,736
Name
Georgia Regents University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
966668691
City
Augusta
State
GA
Country
United States
Zip Code
30912
Luo, Yi; McShan, Daniel L; Matuszak, Martha M et al. (2018) A multiobjective Bayesian networks approach for joint prediction of tumor local control and radiation pneumonitis in nonsmall-cell lung cancer (NSCLC) for response-adapted radiotherapy. Med Phys :
Wang, Shulian; Campbell, Jeff; Stenmark, Matthew H et al. (2018) A model combining age, equivalent uniform dose and IL-8 may predict radiation esophagitis in patients with non-small cell lung cancer. Radiother Oncol 126:506-510
Hawkins, Peter G; Boonstra, Philip S; Hobson, Stephen T et al. (2018) Prediction of Radiation Esophagitis in Non-Small Cell Lung Cancer Using Clinical Factors, Dosimetric Parameters, and Pretreatment Cytokine Levels. Transl Oncol 11:102-108
Sun, Yilun; Hawkins, Peter G; Bi, Nan et al. (2018) Serum MicroRNA Signature Predicts Response to High-Dose Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 100:107-114
Kong, Feng-Ming Spring; Li, Ling; Wang, Weili et al. (2018) Greater reduction in mid-treatment FDG-PET volume may be associated with worse survival in non-small cell lung cancer. Radiother Oncol :
Wang, Weili; Huang, Lei; Jin, Jian-Yue et al. (2018) IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients. Cancer Res 78:809-816
Owen, Daniel Rocky; Boonstra, Phillip S; Viglianti, Benjamin L et al. (2018) Modeling Patient-Specific Dose-Function Response for Enhanced Characterization of Personalized Functional Damage. Int J Radiat Oncol Biol Phys 102:1265-1275
Ellsworth, Susannah G; Rabatic, Bryan M; Chen, Jie et al. (2017) Principal component analysis identifies patterns of cytokine expression in non-small cell lung cancer patients undergoing definitive radiation therapy. PLoS One 12:e0183239
Smeltzer, Matthew P; Lin, Chun Chieh; Kong, Feng-Ming Spring et al. (2017) Survival impact of postoperative therapy modalities according to margin status in non-small cell lung cancer patients in the United States. J Thorac Cardiovasc Surg 154:661-672.e10
Kong, Feng-Ming; Ten Haken, Randall K; Schipper, Matthew et al. (2017) Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer: A Phase 2 Clinical Trial. JAMA Oncol 3:1358-1365

Showing the most recent 10 out of 38 publications